MIMS® Retrospective Chart Review
ConditionOpen Angle Glaucoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorSanoculis Ltd
About this trial
This is a post-market clinical follow-up, retrospective chart review of MIMS® surgical procedures conducted during time period between Sep 2023 and May 2025.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Eye treated with MIMS® Device as a standalone procedure
MIMS® surgery was performed between 27 Sep 2023 and 30 April 2024
Disqualifiers
None
Trial population
The study population consists of subjects of Armenian descent that were treated with the MIMS® Device as a standalone procedure between 27 Sep 2023 and 30 April 2024.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Minimally Invasive Micro Sclerostomy
DeviceThe MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: MIMS Surgery Cohort1 intervention
Trial outcomes
Primary outcomes
1
Change in IOP from medicated baseline at 12 months post-MIMS® surgery
Time frame
Medicated baseline at 12 months post-MIMS® surgery2
Change in the number of topical IOP-lowering medications from medicated baseline at 12 months post-MIMS® surgery
Time frame
Medicated baseline at 12 months post-MIMS® surgery3
Success rate at 12 months post-MIMS® surgery
Time frame
12 months post-MIMS® surgerySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: